Most of these are expressed in cancerous B cells from B-ALL patients from31 (80 with mean FPKM [fragments per kilobase of transcript per million mapped reads] > 10; Supplementary Fig. 7b) and could thus modulate CD19 splicing. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.